Current:Home > StocksFDA authorizes first revamp of COVID vaccines to target omicron-LoTradeCoin
FDA authorizes first revamp of COVID vaccines to target omicron
View Date:2024-12-24 00:13:13
The Food and Drug Administation authorized reformulated versions of the Moderna and Pfizer-BioNTech vaccines that aim to protect against the omicron variant.
The new shots target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now. This double-barreled vaccine is called a bivalent vaccine.
"The FDA has been planning for the possibility that the composition of the COVID-19 vaccines would need to be modified to address circulating variants. ... We have worked closely with the vaccine manufacturers to ensure the development of these updated boosters was done safely and efficiently," said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, in an agency statement. "The FDA has extensive experience with strain changes for annual influenza vaccines. We are confident in the evidence supporting these authorizations."
The Moderna COVID-19 vaccine is authorized for use as a single booster dose in people 18 and older. The Pfizer-BioNTech booster is authorized for people 12 years and up. People are eligible for the new boosters two months after completing their initial vaccination or their last booster shot.
The federal government plans to make the boosters available starting next week. In advance of the FDA's decision, Dr. Ashish Jha, the White House COVID-19 Response Coordinator told NPR that the new boosters represented "a really important moment in this pandemic."
Public health officials hope they will help contain a possible fall and winter surge.
But there is also skepticism about how big a difference the boosters can make. "It could be problematic if the public thinks that the new bivalent boosters are a super-strong shield against infection, and hence increased their behavioral risk and exposed themselves to more virus," John Moore, an immunologist at Weill Cornell Medicine in New York, told NPR before the FDA decision.
veryGood! (17)
Related
- Wheel of Fortune Contestant Goes Viral Over His Hilariously Wrong Answer
- A boss bought scratch-off lottery tickets for her team. They won $50,000.
- 2 snowmachine riders found dead after search in western Alaska
- BP denies ex-CEO Looney a $41 million payout, saying he misled the firm over work relationships
- Amazon's 'Cross' almost gets James Patterson detective right: Review
- Oprah Winfrey Reveals She's Using a Weight-Loss Medication
- Longtime Kentucky Senate leader Damon Thayer says he won’t seek reelection in 2024
- Hackers had access to patient information for months in New York hospital cyberattack, officials say
- The White Stripes drop lawsuit against Donald Trump over 'Seven Nation Army' use
- Ancestry, 23&Me and when genetic screening gifts aren't fun anymore
Ranking
- Deommodore Lenoir contract details: 49ers ink DB to $92 million extension
- This $359 Kate Spade Bucket Bag Is Now Just $75 & It Looks Good With Literally Every Outfit
- Ricardo Drue, soca music star, dies at 38: 'This is devastating'
- Oprah Winfrey Defends Drew Barrymore From Criticism Over Interview Behavior
- Trump pledged to roll back protections for transgender students. They’re flooding crisis hotlines
- 2 Los Angeles County men exonerated after spending decades in prison
- Pakistan court says military trials can resume for 103 supporters of Imran Khan
- News outlets and NGOs condemn Hungary’s new ‘sovereignty protection’ law as a way to silence critics
Recommendation
-
It's cozy gaming season! Video game updates you may have missed, including Stardew Valley
-
She won her sexual assault case. Now she hopes the Japanese military changes so others don’t suffer
-
James Patterson awards $500 bonuses to 600 employees at independent bookstores
-
Luke Combs helping a fan who almost owed him $250,000 for selling unauthorized merchandise
-
All the Ways Megan Fox Hinted at Her Pregnancy With Machine Gun Kelly
-
Oklahoma City voters approve sales tax for $900 million arena to keep NBA’s Thunder through 2050
-
Switzerland’s Greens fail in a long-shot bid to enter the national government
-
Switzerland’s Greens fail in a long-shot bid to enter the national government